Colorectal Cancer

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Richard Kim, MD, on efficacy data for NT-I7 plus pembrolizumab in pretreated microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma.

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

Chun Chao, MS, PhD, discusses the impact of broad-spectrum antibiotic use on the risk of developing early-onset colorectal adenocarcinoma.

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

Christos Kyriakopoulos, MD discusses two correlative studies conducted within the CHAARTED2 trial.

Chiara Cremolini, MD, discusses the role of ctDNA in assessing minimal residual disease in patients with CRC.

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Celecoxib plus adjuvant chemotherapy led to extended DFS and OS vs placebo plus adjuvant chemotherapy in PIK3CA-mutated stage III colon cancer.

First-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.

The European Commission has approved fruquintinib for select patients with pretreated metastatic colorectal cancer.

The FDA has approved adagrasib plus cetuximab for patients with KRAS G12C–mutant locally advanced or metastatic colorectal cancer.

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

Rene Adam, MD, PhD, discusses the use of chemotherapy and liver transplant in patients with definitively unresectable colorectal liver metastases.

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

Integrating liver transplantation into treatment with chemotherapy improved survival at 5 years vs chemotherapy alone in patients with definitively unresectable CRC liver metastases.

Here is your guide to important regulatory approvals made by the FDA in May 2024.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.